The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.
An article from
Startup launches
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.
Published June 22, 2026
Getty Images
La biotech française Bionyra lève 143 millions d’euros pour s’attaquer aux maladies inflammatoires chroniques
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Biogen (NASDAQ:BIIB)
TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million
Le fonds wavrien Vives participe à une Série A de 143 millions dans la biotech Bionyra Pharma
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration
ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M
Avec cette enveloppe, la biotech veut amorcer la mise au point d’une nouvelle génération de biothérapies destinées à soigner les…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's…
NINGBO, China, June 22, 2026 /PRNewswire/ -- TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary,…
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and…
